VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL
18 May 2021
Read more about how REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.
19 April 2021
Read about REPROCELL Bioserve's launch of new clinical oncology diagnostic services featuring NGS-based genomic profiling, targeting a wide range of cancers
Launch of New Testing Service of Identification for Covid-19 Variants
08 April 2021
REPROCELL has launched a new testing service of identification for Covid-19 variants using Allplex SARS-CoV-2 Variants I Assay manufactured by Seegene Inc.
REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan
22 March 2021
Find out more about REPROCELL's collaboration with Blacktrace Holdings Ltd in the domestic sales of their Nadia series: a single-cell analytical system.
REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products
17 March 2021
We are pleased to announce that the REPROCELL Regenerative Medicine Center has been certified as a manufacturing facility for cell culture products.
Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India
11 March 2021
Read Bioserve Biotechnologies announcement about it's new, non invasive prenatal testing service. Providing Preimplantation Genetic Screening and Diagnosis
REPROCELL launches PCR Testing Service for COVID-19
01 March 2021
Read REPROCELL's announcement that it will launch a new PCR testing service for COVID-19 from March 2021 in collaboration with DNAFORM Inc.
REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®
25 February 2021
Read about the phase II clinical trial of Stemchymal, where the safety and efficacy of the regenerative therapeutic will be evaluated in patients with SCA.
REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers
17 December 2020
Find out more about REPROCELL's announcement that they will launch a new service to generate individual specific induced pluripotent stem cells (iPSC's)
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
17 August 2020
REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
REPROCELL’s Personal iPS Service is Launched in Japan
15 July 2020
Read more about REPROCELL's exciting new launch of its Personal iPS service, allowing customers to store cells for future regenerative medicine treatment.
Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient
28 February 2020
REPROCELL is pleased to announce that the first patient has been registered and been administrated at for the Phase II clinical trial of Stemchyma.
Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan
01 August 2018
Read the Japan Pharmaceuticals and Medical Device Agency's announcement that REPROCELL has acheived PMDA Approval of CTN for Phase II Trial of Stemchymal
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
22 November 2016
REPROCELL announces an entrustment contract with Healios K.K. for sample testing support of human clinical trials conducted by Healios.
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
11 November 2016
Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.